Unexpected favorable response of stage IV gastric adenocarcinoma to sintilimab combined with chemotherapy: A case report
Gastric cancer is the fifth most common and the third deadliest type of cancer worldwide. Standard treatment protocols for advanced, unresectable or recurrent cases usually involve combination regimens. These regimens typically consist of a fluoropyrimidine and a platinum agent, with the anti-HER2 monoclonal antibody t...